Irbesartan is projected to be cost and life saving in a Spanish setting for treatment of patients with type 2 diabetes, hypertension, and microalbuminuria

Kidney International, Supplement

Volumn 67, Issue 93, 2005, Pages

  Palmer, Andrew J ^a   Annemans, Lieven ^b   Roze, Stéphane ^b   Lapuerta, Pablo ^b   Chen, Roland ^b   Gabriel, Sylvie ^b   Carita, Paulo ^b   Rodby, Roger A ^b   De Zeeuw, Dick ^b   Parving, Hans Henrik ^b   De Alvaro, Fernando ^b  

^a IQVIA   (United States)

^b NONE

Author keywords

Cost effectiveness; Costs; End stage renal disease; Irbesartan; Microalbuminuria; Modeling; Nephropathy; Spain

Indexed keywords

ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIURETIC AGENT; IRBESARTAN; BIPHENYL DERIVATIVE; TETRAZOLE DERIVATIVE;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CONFERENCE PAPER; CONTROLLED STUDY; COST CONTROL; CREATININE BLOOD LEVEL; DISEASE COURSE; HEALTH CARE COST; HUMAN; HYPERTENSION; INCIDENCE; KIDNEY DISEASE; KIDNEY FAILURE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MICROALBUMINURIA; MONTE CARLO METHOD; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SPAIN; STANDARD; ALBUMINURIA; ARTICLE; BLOOD PRESSURE; ECONOMICS; PHYSIOLOGY; PROBABILITY; CLINICAL TRIAL;

ALBUMINURIA; ANTIHYPERTENSIVE AGENTS; BIPHENYL COMPOUNDS; BLOOD PRESSURE; COST SAVINGS; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERTENSION; LIFE EXPECTANCY; MARKOV CHAINS; SPAIN; TETRAZOLES;

EID: 19944391902     PISSN: 00986577     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1523-1755.2005.09312.x     Document Type: Conference Paper

References (10)

1. LORENZO V, MARTIN UB: Epidemiologic analysis of the increase in terminal renal insufficiency associated with type 2 diabetes mellitus. Nefrologia 20(Suppl 5):77-81, 2000
2. PEREZ GR, RODRIOUEZ BP, DALL'ANESSE C, et al: Pre-occupying increase in diabetes as cause for terminal kidney failure. Evaluation of treatment strategies. Ann Med Intern 18:175-180, 2001
3. CARRETERO-DIOS D, PEREZ-GARCIA R, RODRIOUEZ-BENITEZ P, et al: Diabetes mellitus as cause of terminal renal failure. An epidemic of the 21st century? Nefrologia 21(Suppl 3):83-87, 2001
4. PARVING H-H, LEHNERT H, BROCHNER-MORTENSEN J, et al: The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:910-912, 2001
5. LEWIS EJ, HUNSICKER LG, CLARKE WR, et al: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860, 2001
6. BRENNER BM, COOPER ME, DE ZEEUW D, et al: Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869, 2001
7. PALMER AJ, ANNEMANS L, ROZE S, et al: The cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding angiotensin converting enzyme inhibitors, other angiotensin-2-receptor antagonists and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease. Diabetes Care 27:1897-1903, 2004
8. BRIGGS AH: Handling uncertainty in cost-effectiveness models. Pharmacoeconomics 17:479-500, 2000
9. TREEAGE SOFTWARE, INC: DATA™ Pro Healthcare Users Manual, Williamstown, TreeAge Software, Inc., 1997
10. PALMER AJ, ANNEMANS L, ROZE S, et al: Cost-effectiveness of irbesartan in patients with type 2 diabetes, hypertension and nephropathy: A Spanish perspective. Nefrologia 24:231-238, 2004